All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

When sequencing therapies for RRMM, how can we identify which patients may benefit most from CAR-T?

During the 2021 ASCO Annual Meeting and the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US. We asked, When sequencing therapies for relapsed/refractory multiple myeloma (RRMM), how can we identify which patients may benefit most from chimeric antigen receptor (CAR) T- cell therapy?

In this video, Munshi discusses the effectiveness and benefits of CAR T-cell therapy for different subsets of heavily pretreated patients with MM. However, he points out that all patients should be willing to adhere to the requirements of a CAR T-cell treatment program, including close follow-up and monitoring, and frequent clinic visits in the outpatient setting.

 

Share: